2014-06-17 20:07:56 UTC

Therapeutic Treatment for Celiac Disease Proves Effective in Phase 2 Trial

June 19, 2014

Marja-Leena Lähdeaho and colleagues report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease, necessitating strict life-long exclusion of dietary gluten. Despite adherence to a gluten-free diet, many patients remain symptomatic and still have small intestinal inflammation. In this case, nondietary therapies are needed. Marja-Leena Lähdeaho and colleagues investigated the ability of ALV003, a mixture of two recombinant gluten-specific proteases given orally, to protect patients with celiac disease from gluten-induced mucosal injury in a phase II trial. They report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gastroenterology 2014: 146(7): 1649-1658

More on Celiac Disease

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Avoidance of Cow's Milk–Based Formula for At-Risk Infants Does Not Reduce Development of Celiac Disease: A Randomized Controlled Trial

Oct. 1, 2017

Increased cow's milk antibody titers before the appearance of anti-TG2A and celiac disease indicates that subjects with celiac disease might have increased intestinal permeability in early life.

Can You Name the Top Five Products with Gluten?

Sept. 20, 2017

This month’s CGH patient education section provides you with top talking points for your celiac disease patients.